Bharatbook added a new report on “Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1″ into its market report catalogue for reselling.
 
 Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1
 
 Report Details
 
 This report provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering: ( http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html )
 
 • Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
 • Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
 • Region wise Diabetes Health Expenditure and Mortality
 • Top 10 Countries Diabetes Population and Future Forecast
 • Top 5 Countries Diabetes Drug Market and Future Forecast
 • Top 7 Countries Insulin Market and Future Forecast
 • Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
 • Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
 • Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
 • Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market
 
 Research Highlights
 
 • USA controls more than 50% of the total Diabetes Drug market share in 2009
 • Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
 • China will have the second highest Insulin market share by 2012 replacing Germany
 • DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
 • GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
 • Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
 • Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
 • Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
 • Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists
 • China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
 • Japan Insulin market is expected to be more than US$ 1 Billion by 2010
 
 Key Drugs Analyzed
 
 Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix
 Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus
 DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,
 GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide
 
 To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html
 
 Related Reports
 
 Diabetes Market Forecast to 2015
 http://www.bharatbook.com/detail.asp?id=84122&rt=Diabetes-Market-Forecast-to-2015.html
 
 BRIC Diabetes Drugs Market
 http://www.bharatbook.com/detail.asp?id=134449&rt=BRIC-Diabetes-Drugs-Market.html
 
 Or
 
 Contact us at :
 
 Bharat Book Bureau
 Tel: +91 22 27578668
 Fax: +91 22 27579131
 Email: info@bharatbook.com
 Website: www.bharatbook.com
 Follow us on twitter: http://twitter.com/3bbharatbook